AD-101(Addpharma)
- Generic Name
- AD-101(Addpharma)
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Brain CancerMetastatic Breast CancerMelanoma Stage IVMelanoma RecurrentBreast CancerGBMMetastatic Prostate CancerGlioblastoma MultiformeGlioblastomaProstate Cancer
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Sapience Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT04478279
- Locations
- 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇬🇧University of Leeds, Leeds, United Kingdom
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Sonexa Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01332695
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Sonexa Therapeutics, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT00842673
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Sonexa Therapeutics, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT00842816
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath